Navigation Links
Rockland Immunochemicals, Inc. CSO Opines “Benefits of Polyclonal Antibodies” in peer-reviewed article
Date:8/9/2018

Rockland Immunochemicals, Inc. announced today that Dr. Carl Ascoli, Chief Science Officer at Rockland, and Dr. Birte Aggeler, Director of Antibody Development at Bio-Techne, composed a peer-reviewed article using their combined experience of more than 50 years. The review article was published online on August 9, 2018 and will be printed in the September 2018 issue by the journal BioTechniques. The review article, entitled "The Overlooked Benefits of Polyclonal Antibodies,” discusses the pros and cons of polyclonal, conventional monoclonal, and recombinant monoclonal antibodies, while presenting procedures for experimental design, the inclusion of relevant controls, and validation strategies for polyclonal antibodies.

Antibodies are critical reagents most often used by life science and translational medicine researchers and are transformative tools used to diagnose and treat disease. Many 21st century medical breakthroughs were successful in part to antibody technology. Yet antibodies, especially polyclonal antibodies, are caught in a firestorm of controversary concerning data reproducibility. Ascoli stated “by emphasizing the appropriate role polyclonal antibodies may play in conducting life science research, our efforts here should improve upon the use of antibodies, the collection of reproducible data, and the expansion of antibody-based technologies.”

Thoughtful antibody design and development allows for polyclonal antibodies to be used in many different applications, techniques, and instrumentation. Ascoli explained that “while some have called for polyclonal antibodies to be phased out of research entirely, we believe in using ‘the right tool for the job’ which includes using all forms of antibodies, polyclonal, conventional monclonal, and recombinant monoclonal, in the appropriate context and according to the manufacturer’s recommendations.” When using polyclonal antibodies, it is particularly important to use appropriate positive and negative controls and to assure immunoassay-specific antibody validation on a lot-to-lot basis. This review article presents the value of polyclonal antibodies for research, discusses strategies to minimize their disadvantages, and suggests when other forms of antibodies are more appropriate.

To read the full peer-reviewed article, please visit: https://www.future-science.com/doi/10.2144/btn-2018-0065

# # #

TO THE EDITOR:
Rockland Immunochemicals, Inc., (Rockland) provides the highest quality antibodies and antibody-based life science tools and services to the academic, biopharma, and diagnostic industries for use in basic research, assay development, preclinical and clinical studies, and bioprocessing. With facilities in Pennsylvania for over 55 years, Rockland manufactures products ideally suited for integration into critical assays such as western blotting, immunohistochemistry (IHC), immunofluorescence microscopy (IF), ELISA, flow cytometry, and 2D imaging.
Additional information about Rockland’s life science tools and services can be found on Rockland’s website at http://www.rockland-inc.com.

Christina Rowley
Marketing Communications Manager
Rockland Immunochemicals, Inc.
Phone: 484.791.3823
Email: christina.rowley(at)rockland-inc.com

Read the full story at https://www.prweb.com/releases/rockland_immunochemicals_inc_cso_opines_benefits_of_polyclonal_antibodies_in_peer_reviewed_article/prweb15670368.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology technology :

1. Rockland Immunochemicals, Inc. Partners with Alex’s Lemonade Stand Foundation to Support Early Career Childhood Cancer Researchers
2. The Binding Site & Rockland Immunochemicals Enter Into Distribution Agreement
3. Rockland Immunochemicals, Inc. Introduces Melanoma Cell Lines in Collaboration with The Wistar Institute
4. uBiome Publishes Peer-Reviewed Scientific Paper in PLOS ONE on First Version of Technology for Gut Health Screening Test
5. Amarantus Announces Peer-Reviewed Publication Further Describing Mechanisms of Action for Eltoprazine in the Treatment of Parkinsons LID
6. CardioCell Board Members and Clinical Trial Leads Collaborate on Peer-Reviewed Paper Published in the Journal of Cardiovascular Medicine
7. Peer-Reviewed Study in Cell Validates eFFECTOR Therapeutics Novel Small-Molecule Approach to Cancer Treatment
8. Mechanism of Action of ABIVAXs First-in-class Anti-HIV Drug Published Today in Peer-reviewed Journal Retrovirology
9. Newly Released Peer-Reviewed Publication Further Validates RepliCels Use of Dermal Sheath Cup Cells to Treat Pattern Baldness
10. MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal
11. Fifth MiMedx Scientific Study Published In Peer-Reviewed Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/3/2018)... (PRWEB) , ... November 01, 2018 , ... ... Metrics Champion Consortium Summit. Dr. Jean Mulinde, Senior Advisor, Division of Clinical Compliance ... risk, monitor safety and ensure data reliability. , What should clinical research industry ...
(Date:10/31/2018)... ... October 30, 2018 , ... ... to be a very important aspect of experimental biology. Reproducibility of cell-based assays ... data. Despite of choosing the appropriate assay type, there are many more factors ...
(Date:10/24/2018)... ... 22, 2018 , ... uBiome, the leader in microbial genomics, ... Institute, Stephenson Chair of Data Science, and Professor in the Department of Biomedical ... scientists and doctors from around the world, Dr. Bourne will bring to uBiome ...
(Date:10/18/2018)... , ... October 18, 2018 , ... With rapid technological ... and store their eggs. Previously reserved for women facing a cancer diagnosis requiring chemotherapy ... so to preserve their options. Simply put, they do not want to get ...
Breaking Biology Technology:
(Date:10/31/2018)... ... October 30, 2018 , ... ODSC West 2018, the latest in the ... through Nov. 3. The event offers more than 200 training sessions and workshops led ... striving to advance the state of the art. , ODSC West 2018 will ...
(Date:10/26/2018)... ... October 26, 2018 , ... uBiome, the leader ... of Sapphire Women’s Health Group and prominent women’s health expert, to its Medical ... world, Dr. Moore will bring to uBiome her expertise on women’s health including ...
(Date:10/25/2018)... ... October 25, 2018 , ... ... Food and Drug Administration (FDA) Center for Biologics Effectiveness and Research (CBER) for ... expand and enhance current capabilities with respect to data sources, infrastructure, methods, and ...
Breaking Biology News(10 mins):